TRU - Truscreen

[HITMAN]

Yeh, % YEAR LOW, IMHO get out while TRU is above .04 !

I'm in buy mode at the moment. Feel free to sell to me at these prices.

[HITMAN]

https://youtu.be/W3bkHMAEbj4

[Sideshow Bob]

https://www.nzx.com/announcements/403187

TruScreen unaudited interim results for the half-year ended 30 September 2022
Highlights for Half Year ended 30 September 2022
• Revenue in line with prior year, in face of challenging market conditions
• Further growth potential in China on relaxation of COVID restrictions
• Developments in Vietnam, Saudi Arabia, Mexico, eastern Europe should produce results in year ahead
• Appointment of CEO, Dr Beata Edling

[Balance]

Train wreck.

[whatsup]

Train wreck.

Why are we surprised, please read its history, imo even at .00001 the fish heads are ahead , no wonder its being constantly being pumped !!

[HITMAN]

Constantly pumped, or constantly slammed.

Disappointed with result as growth in last period was great. Hoping to see that continue. China as there main growth market went backwards with ongoing Covid zero playing a big part. Steps are still going, but timing is big as cashflow burn is there. They’ve dropped down to core staff and paid out redundancy. The ship is still sailing but taking on some water.

A victim of current world issues, I’m certain the product has a huge future, but who gets to bring it to market. It saves lives, is cost effective, and saves time and resources. Ground work is certainly being done.

Covid zéro in china can’t go on for ever, the rest of the world has accepted it.

[Pegasus2000]

China Ramps Up for Public Health Check Centres
TRU
08/03/2023 09:15
GENERAL
NOT PRICE SENSITIVE
REL: 0915 HRS TruScreen Group Limited

GENERAL: TRU: China Ramps Up for Public Health Check Centres

NZX/ASX Announcement

8 March 2023

China Ramps Up for Public Health Check Centres

Highlights

o China distributor orders 40 devices for April 2023 delivery
o First TruScreen Health Check installation in February 2023
o Further tender won in major public hospital

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that its China
distributor, Beijing Siweixiantai Tech Co. Ltd (SWXT), has placed an order
for 40 TruScreen cervical cancer screening devices for installation into
China's growing public Health Check Sector. Delivery is expected in April
2023.

Following long COVID delays the initial installation of TruScreen into the
public Health Check Centre within The People's Liberation Army General
Hospital, one of the leading health check centers in the country was
completed in February 2023. This is the first installation into a public
Health Check Centre and SWXT is expecting rapid growth in the year ahead.

TruScreen won the tender in February 2023 for Affiliated Hospital of Nantong
University in Nantong, Jiangsu Province. The hospital is one of the largest
in the province and is highly regarded in North Jiangsu. The head of its
Obstetric and Gynecologic Department is the current Chair of COGA Jiangsu
Provincial branch (see NZX/ASX announcement dated 5 April 2022).

China, after the COVID lockdown years, is now seeing a strong pipeline of
significant growth opportunities. This includes 7 hospital tenders won
with 13 installations pending, 23 hospitals where TruScreen has been approved
and waiting for tender outcomes, and 78 hospitals where Obstetric and
Gynecologic Department acceptance have been received and are waiting for the
next stage of hospital approval.

This announcement has been approved by the Board.
Ends

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au
End CA:00407991 For:TRU Type:GENERAL Time:2023-03-08 09:15:53

[Walter]

Hopefully they can survive long enough for sales to get traction. Good recent news, but growth may be too slow and too little.

[jonu]

Truscreen on a tear today on the back of two nice announcements.

Discl: holding

[Walter]

New China cervical cancer screening guideline announced by CSCCP to include Truscreen’s optical electrical technology
Highlights
• First national medical guideline in the world to recommend TruScreen technology, expected to drive further sales
• China Cervical Cancer Screening Management Guideline (Guideline) of Chinese Society for Colposcopy and Cervical Pathology (CSCCP) endorses TruScreen technology as an Artificial Intelligence Screening Method
• The Guideline endorses TruScreen technology as a new method for cervical cancer screening in China
Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that the TruScreen technology has been endorsed in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline, one of the most important specialist medical clinical guidelines governing management of cervical cancer. The news was recently released in a media conference at the first event of the annual CSCCP congress in Beijing.
CSCCP’s decision to include TruScreen technology in its new Guideline emphasises the role of new technology in a booming Chinese healthcare sector. The decision is based on the body of evidence supporting TruScreen clinical use world-wide and after extensive consultations with healthcare practitioners and decision makers.
CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the burden of cervical cancer worldwide. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare providers as well as government bodies.